Bioventus Q4 GAAP EPS $0.21, revenue $157.9M; guides FY2026 sales $600-610M

Bioventus Inc.

Q4 revenue $157.9M (+2.8% reported, +10.0% organic); GAAP EPS $0.21 (vs $0.00); non-GAAP EPS $0.24; Adj. EBITDA $36.7M (+30%).
Full year 2025 revenue $568.1M (-0.9% reported, +7.5% organic); GAAP EPS $0.33 (vs -$0.56); Adj. EPS $0.68 (+21.4%).
FY2026 guidance: net sales $600-610M (6-7% growth); Adj. EPS $0.73-$0.77 (7-13% growth); cash from ops $82-87M.
Q4 cash from operations $38M (+97% YoY); full year cash from ops up 92%; debt reduced by $29M in Q4.
Launched PNS products StimTrial and TalisMann; added Megan Rosengarten as SVP/GM PNS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.